[go: up one dir, main page]

PE20081194A1 - Produccion de glicoproteinas - Google Patents

Produccion de glicoproteinas

Info

Publication number
PE20081194A1
PE20081194A1 PE2007000892A PE2007000892A PE20081194A1 PE 20081194 A1 PE20081194 A1 PE 20081194A1 PE 2007000892 A PE2007000892 A PE 2007000892A PE 2007000892 A PE2007000892 A PE 2007000892A PE 20081194 A1 PE20081194 A1 PE 20081194A1
Authority
PE
Peru
Prior art keywords
glycoprotein
crop
concentration
temperature range
allow
Prior art date
Application number
PE2007000892A
Other languages
English (en)
Inventor
Daniel Lasko
Steve Koza
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38645762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081194(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20081194A1 publication Critical patent/PE20081194A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN METODO PARA PRODUCIR UNA GLICOPROTEINA TAL COMO EL FACTOR DE COAGULACION HUMANO RECOMBINANTE IX O UN ANTICUERPO MONOCLONAL IgG1 PEPTIDICO ANTI-ABETA HUMANIZADO EN UN CULTIVO CELULAR QUE COMPRENDE: A) CULTIVAR CELULAS DE MAMIFEROS QUE CONTIENEN UN GEN QUE CODIFICA UNA GLICOPROTEINA DE INTERES EN UN MEDIO DE CULTIVO CELULAR QUE COMPRENDE MANGANESO EN UNA CONCENTRACION DE 10nM A 600nM; B) MANTENER EL CULTIVO EN UN PRIMER RANGO DE TEMPERATURA DE 37 ºC DURANTE UN TIEMPO SUFICIENTE PARA PERMITIR A LAS CELULAS REPRODUCIRCE HASTA UNA DENSIDAD CELULAR VIABLE DE 20% A 80%; C) CAMBIAR EL CULTIVO A UN SEGUNDO RANGO DE TEMPERATURA DE 31 ºC DURANTE UN TIEMPO SUFICIENTE PARA PERMITIR LA EXPRESION DE LA GLICOPROTEINA, EN DONDE EL PATRON DE GLICOSILACION DE LA GLICOPROTEINA EXPRESADA ES MAS EXTENSO QUE EL PATRON DE GLICOSILACION OBSERVADO EN CARENCIA DE MANGANESO. DICHO MEDIO DE CULTIVO COMPRENDE ADEMAS GLUTAMINA EN UNA CONCENTRACION DE 8mM Y COMPONENTES SUPLEMENTARIOS TAL COMO HORMONAS, IONES INORGANICOS, VITAMINAS, GLUCOSA, ENTRE OTROS
PE2007000892A 2006-07-13 2007-07-11 Produccion de glicoproteinas PE20081194A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83065806P 2006-07-13 2006-07-13

Publications (1)

Publication Number Publication Date
PE20081194A1 true PE20081194A1 (es) 2008-09-22

Family

ID=38645762

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000892A PE20081194A1 (es) 2006-07-13 2007-07-11 Produccion de glicoproteinas

Country Status (23)

Country Link
US (1) US8129145B2 (es)
EP (3) EP2495307B9 (es)
JP (1) JP5401310B2 (es)
KR (1) KR101495549B1 (es)
CN (2) CN101541950A (es)
AR (1) AR061976A1 (es)
AU (1) AU2007272957B2 (es)
BR (1) BRPI0714212B8 (es)
CA (1) CA2657248C (es)
DK (3) DK2041270T3 (es)
ES (2) ES2668212T3 (es)
HK (1) HK1214307A1 (es)
HU (1) HUE039128T2 (es)
IL (1) IL196252A (es)
MX (1) MX2009000349A (es)
PE (1) PE20081194A1 (es)
PL (2) PL2041270T3 (es)
PT (2) PT2495307T (es)
RU (1) RU2463345C2 (es)
SI (1) SI2495307T1 (es)
TR (1) TR201807021T4 (es)
TW (1) TW200812577A (es)
WO (1) WO2008008360A1 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
RU2463345C2 (ru) 2006-07-13 2012-10-10 Вайет Получение гликопротеинов
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
RU2518289C2 (ru) 2006-09-13 2014-06-10 Эббви Инк, Способ получения антитела или его фрагмента с подпиткой (варианты)
JP5401319B2 (ja) * 2006-11-03 2014-01-29 ワイス・エルエルシー 細胞培養における解糖阻害物質
KR20090127326A (ko) * 2007-03-02 2009-12-10 와이어쓰 폴리펩티드의 생산을 위한 세포 배양물 중에서 구리 및 글루타메이트의 용도
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
US20090233334A1 (en) * 2008-03-11 2009-09-17 Excellgene Sa Cell cultivation and production of recombinant proteins by means of an orbital shake bioreactor system with disposable bags at the 1,500 liter scale
TW201024318A (en) 2008-10-20 2010-07-01 Abbott Lab Isolation and purification of antibodies using protein A affinity chromatography
NZ592097A (en) 2008-10-20 2013-01-25 Abbott Lab Viral inactivation during purification of il-12 and il-18 antibodies
EP3009447B1 (en) * 2009-07-24 2018-06-06 Dr. Reddy's Laboratories, Ltd. Production of erythropoiesis stimulating protein using metal ions
MX344786B (es) * 2009-07-28 2017-01-06 Shire Human Genetic Therapies Composiciones y metodos para tratar enfermedad de gaucher.
EP3862423A1 (en) 2010-04-26 2021-08-11 Novartis AG Improved cell cultivation process
JP6001456B2 (ja) * 2010-12-28 2016-10-05 中外製薬株式会社 動物細胞の培養方法
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
RU2580020C2 (ru) 2011-04-29 2016-04-10 Биокон Рисерч Лимитед Способ снижения гетерогенности антител и способ получения соответствующих антител
JP2014527518A (ja) 2011-07-20 2014-10-16 ゼプテオン インコーポレイテッド ポリペプチド分離法
US10059770B2 (en) 2012-01-30 2018-08-28 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of a glycoprotein composition
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
WO2014170866A2 (en) * 2013-04-18 2014-10-23 Dr. Reddy's Laboratories Limited Process of obtaining glycoprotein composition with increased galactosylation content
JP2016527911A (ja) * 2013-08-20 2016-09-15 レック・ファーマシューティカルズ・ディー・ディーＬｅｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｄ．Ｄ． ポリペプチドのα−アミド化および／またはＣ末端アミノ酸開裂を制御するための細胞培養用培地およびプロセス
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3110941A4 (en) * 2014-02-25 2017-10-18 Dr. Reddy's Laboratories Ltd. Process for modifying galactosylation and g0f content of a glycoprotein composition by glutamine supplementation
SI3110961T1 (sl) * 2014-02-27 2020-03-31 F. Hoffmann-La Roche Ag Modulacija rasti celic in glikozilacije pri rekombinantni proizvodnji glikoproteina
PL3227454T3 (pl) 2014-12-01 2020-07-27 Amgen Inc. Sposób manipulowania poziomem zawartości glikanów w glikoproteinie
KR102007930B1 (ko) * 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
EP3042952A1 (en) * 2015-01-07 2016-07-13 CEVEC Pharmaceuticals GmbH O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
CA2986625A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Methods for preparing modified von willebrand factor
EP3303559A1 (en) * 2015-06-01 2018-04-11 Biogen MA Inc. Manganese supplementation for control of glycosylation in mammalian cell culture process
CN104894055B (zh) * 2015-06-15 2018-07-17 成都金凯生物技术有限公司 一种优化的细胞培养基、细胞培养方法及其在制备蛋白和抗体中的应用
KR101932137B1 (ko) * 2017-01-02 2018-12-24 연세대학교 산학협력단 당화 증강용 조성물 및 당화 증강된 단백질의 제조방법
WO2018210771A1 (en) 2017-05-17 2018-11-22 Octapharma Ag Method for the production of a recombinant target protein
HU231514B1 (hu) * 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
AU2019379858B2 (en) 2018-11-13 2024-01-04 Janssen Biotech, Inc. Control of trace metals during production of anti-CD38 antibodies
JP2020188737A (ja) * 2019-05-23 2020-11-26 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体の製造方法
EP3906249A1 (en) 2019-12-06 2021-11-10 Regeneron Pharmacetucals, Inc. Anti-vegf protein compositions and methods for producing the same
JP2023538881A (ja) * 2020-08-14 2023-09-12 ブリストル－マイヤーズ スクイブ カンパニー タンパク質の製造方法
US20240150723A1 (en) * 2021-03-23 2024-05-09 Biogen Ma Inc. Reducing host cell impurities during recombinant protein production

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
NO162160C (no) 1987-01-09 1989-11-15 Medi Cult As Serumfritt vekstmedium, samt anvendelse derav.
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
SU1587450A1 (ru) * 1988-05-04 1990-08-23 Институт биоорганической химии АН БССР Способ разделени гликозилированной и негликозилированной форм пролактина биологического материала
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US5156964A (en) 1990-08-16 1992-10-20 Cetus Corporation Methods for adapting cells for increased product production through exposure to ammonia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
US5118816A (en) 1990-12-26 1992-06-02 American Cyanamid Company 2-aryl-5-(trifluoromethyl)-2-pyrroline compounds useful in the manufacture of insecticidal, nematocidal and acaricidal arylpyrroles
EP0568575B2 (en) 1991-01-21 2010-11-03 Elan Pharmaceuticals, Inc. Test and model for alzheimer's disease
EP1589107B1 (en) 1992-08-21 2009-12-23 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
EP0958364A4 (en) 1996-10-23 2001-10-31 Univ Pennsylvania IMMUNOTHERAPY AND IMPROVED VACCINES
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
WO1999035255A2 (en) 1998-01-12 1999-07-15 Betagene, Inc. Compositions and methods for regulated secretion from neuroendocrine cell lines
KR100743894B1 (ko) 1998-02-27 2007-07-30 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 백신, 면역치료제 및 그의 이용 방법
JP4673974B2 (ja) 1998-09-30 2011-04-20 ワイス・ホールディングズ・コーポレイション アジュバントとしての変異コレラホロトキシン
AU778046B2 (en) * 1999-04-26 2004-11-11 Genentech Inc. Cell culture process for glycoproteins
JP2001120262A (ja) * 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
CZ303929B6 (cs) 2000-03-22 2013-07-03 Octapharma Biopharmaceuticals Gmbh Mutein faktoru VIII, odpovídající DNA sekvence, vektor a hostitelská bunka, farmaceutická kompozice, zpusob produkce muteinu a imortalizovaná lidská bunecná linie
US20040001822A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
CN1297316C (zh) 2001-06-07 2007-01-31 惠氏控股有限公司 作为佐剂的霍乱全毒素的突变体形式
EP1404279A4 (en) 2001-06-07 2007-08-08 Wyeth Corp MUTANT FORMS OF CHOLERA HOLOTOXIN AS ADJUVANT
HUE030806T2 (hu) 2002-05-02 2017-05-29 Wyeth Holdings Llc Calicheamicin származék-hordozó konjugátumok
PL376381A1 (en) 2002-07-15 2005-12-27 Immunex Corporation Methods and media for controlling sialylation of proteins produced by mammalian cells
TWI364458B (en) * 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
TWI374935B (en) * 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
AR058140A1 (es) 2005-10-24 2008-01-23 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
AU2006312014A1 (en) 2005-11-02 2007-05-18 Wyeth Methods for adapting mammalian cells
EP2495308A1 (en) 2005-12-08 2012-09-05 Amgen Inc. Improved production of glycoproteins using manganese
RU2463345C2 (ru) 2006-07-13 2012-10-10 Вайет Получение гликопротеинов

Also Published As

Publication number Publication date
US20080081356A1 (en) 2008-04-03
DK2041270T3 (da) 2014-01-27
BRPI0714212A2 (pt) 2013-03-26
PT2041270E (pt) 2013-12-27
ES2668212T9 (es) 2018-05-30
DK2495307T3 (en) 2018-05-07
SI2495307T1 (en) 2018-05-31
CN101541950A (zh) 2009-09-23
AU2007272957B2 (en) 2014-05-01
CA2657248A1 (en) 2008-01-17
ES2440487T3 (es) 2014-01-29
TW200812577A (en) 2008-03-16
RU2008152449A (ru) 2010-08-20
DK3255141T3 (da) 2022-01-31
AR061976A1 (es) 2008-08-10
EP2495307A1 (en) 2012-09-05
WO2008008360A1 (en) 2008-01-17
IL196252A (en) 2016-02-29
TR201807021T4 (tr) 2018-06-21
ES2668212T3 (es) 2018-05-17
MX2009000349A (es) 2009-03-09
US8129145B2 (en) 2012-03-06
KR101495549B1 (ko) 2015-02-25
PL2041270T3 (pl) 2014-04-30
EP3255141A1 (en) 2017-12-13
IL196252A0 (en) 2011-08-01
DK2495307T5 (en) 2018-07-16
JP5401310B2 (ja) 2014-01-29
AU2007272957A1 (en) 2008-01-17
HUE039128T2 (hu) 2018-12-28
PL2495307T3 (pl) 2018-07-31
EP2041270B1 (en) 2013-11-20
PT2495307T (pt) 2018-05-10
BRPI0714212B8 (pt) 2021-05-25
EP3255141B1 (en) 2021-12-01
CN104878064A (zh) 2015-09-02
EP2495307B9 (en) 2018-05-02
KR20090029841A (ko) 2009-03-23
EP2495307B1 (en) 2018-02-21
RU2463345C2 (ru) 2012-10-10
HK1214307A1 (zh) 2016-07-22
EP2041270A1 (en) 2009-04-01
CA2657248C (en) 2018-10-30
BRPI0714212B1 (pt) 2021-01-19
JP2009543550A (ja) 2009-12-10

Similar Documents

Publication Publication Date Title
PE20081194A1 (es) Produccion de glicoproteinas
AR066239A1 (es) Metodo para la produccion de proteinas mediante celulas cultivadas
WO2005028626A3 (en) Cell culture media
EP4478049A3 (en) Cancer modeling platforms and methods of using the same
SI1404811T1 (sl) Ogljikov monoksid izboljša rezultate pri presaditvi tkiva in organov ter prepreči apoptozo
GB2432846B (en) Medium and culture of embryonic stem cells
WO2008135991A3 (en) Large scale disposable bioreactor
WO2002076285A3 (en) Composition and methods fro the production of biological tissues and tissue constructs
IL189193A0 (en) Transplastomic plants expressing lumen-targeted protein
AR060827A1 (es) Metodo para bloquear la infeccion por flavivirus, moleculas y usos
PL1863905T3 (pl) Sposób aktywacji naturalnych komórek zabójców preparatami komórek guza in vitro
DK1702979T3 (da) Improved keratinocyte culture and uses thereof
DE602004008453D1 (de) Künstliches immunorgan
ES2657487T3 (es) Agentes de fijación exentos de formalina para tinciones histológicas de muestras de tejidos
CL2020002450A1 (es) Glicoformas afucosiladas totales de anticuerpos producidos en cultivo celular
WO2008153150A1 (ja) Ｎｋ細胞を含む細胞集団の培養方法及び当該細胞集団の利用
DK1689461T5 (da) Anvendelse af en hydrogel til dyrkning af chondrocytter
BR112018012070A2 (pt) método para a produção de tecidos/ órgãos utilizando células sanguíneas
ATE414760T1 (de) Verfahren zur herstellung einer epithelzellen enthaltenden zellzusammensetzung
TW200636068A (en) A method of culturing a cell and use of the same
Wallner et al. Reproducibly oriented cell divisions pattern the prothallus to set up dorsoventrality and de novo meristem formation in Marchantia polymorpha
RU2006146795A (ru) Композиция для стимулирования роста и регенерации клеток, а также способы ее получения
NO20073094L (no) Fremgangsmate for fremstilling av pattedyrceller
BRPI0403200A (pt) Método para recrescimento de células embriogênicas crioconservadas de conìferas
ATE552334T1 (de) Serumfreies medium zur herstellung von retroviralen vektoren

Legal Events

Date Code Title Description
FA Abandonment or withdrawal